mTOR-Dependent Cell Proliferation in the Brain by Ryskalin, Larisa et al.
Review Article
mTOR-Dependent Cell Proliferation in the Brain
Larisa Ryskalin,1 Gloria Lazzeri,1 Marina Flaibani,1 Francesca Biagioni,2
Stefano Gambardella,2 Alessandro Frati,2 and Francesco Fornai1,2
1Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55,
56126 Pisa, Italy
2I.R.C.C.S. Neuromed, Via Atinense 18, Pozzilli, 86077 Isernia, Italy
Correspondence should be addressed to Francesco Fornai; francesco.fornai@med.unipi.it
Academic Editor: Marta M. Alonso
Copyright © 2017 Larisa Ryskalin et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The mammalian Target of Rapamycin (mTOR) is a molecular complex equipped with kinase activity which controls cell viability
being key in the PI3K/PTEN/Akt pathway. mTOR acts by integrating a number of environmental stimuli to regulate cell growth,
proliferation, autophagy, and protein synthesis. These effects are based on the modulation of different metabolic pathways.
Upregulation of mTOR associates with various pathological conditions, such as obesity, neurodegeneration, and brain tumors.
This is the case of high-grade gliomas with a high propensity to proliferation and tissue invasion. GlioblastomaMultiforme (GBM)
is a WHO grade IV malignant, aggressive, and lethal glioma. To date, a few treatments are available although the outcome of GBM
patients remains poor. Experimental and pathological findings suggest that mTOR upregulation plays a major role in determining
an aggressive phenotype, thus determining relapse and chemoresistance. Among several activities, mTOR-induced autophagy
suppression is key in GBM malignancy. In this article, we discuss recent evidence about mTOR signaling and its role in normal
brain development and pathological conditions, with a special emphasis on its role in GBM.
1. Introductory Statement: Molecular
Structure and Functions of mTOR
The mammalian Target of Rapamycin (mTOR) is a 289-kDa
serine/threonine kinase which belongs to the PI3K-related
kinase (PIKK) family. It was originally discovered in yeast in
the early 1990s. mTOR is a highly evolutionarily preserved
kinase and it is ubiquitously expressed in all eukaryotic cell
types including neural cells [1]. This protein is the target
of a molecule named rapamycin, a lipophilic macrolide
compound produced by the bacterium Streptomyces hygro-
scopicus, which was isolated for the first time in the 1970s in a
soil sample fromEaster Island (RapaNui in Polynesian) [2, 3].
This kinase plays a pivotal role in cell growth and
metabolism acting as a key sensor and integrator of a variety
of intra- and extracellular stimuli encompassing nutrients,
growth factors, and energetic status and it represents a down-
stream substrate of PI3K/PTEN/Akt pathway, which controls
protein synthesis and gene transcription, proliferation, and
motility [4–6].
In mammals, the mTOR catalytic subunit interacts with
several proteins to form two big, functionally distinct, mul-
tiprotein complexes known as mTORC1 (mTOR Complex 1)
andmTORC2 (mTORComplex 2) [7–10] (Figure 1). Complex
1 (mTORC1) is composed of the catalytic subunit mTOR, the
regulatory protein Raptor, and the proteins PRAS40, Deptor,
and mLST8. In particular Raptor (regulatory associated
protein of mTOR) acts as a scaffold protein for recruiting
the mTOR substrates [11–13]. mTORC1 also associates with
PRAS40 (proline-rich Akt substrate of 40 kDa) and Deptor
(DEP-domain-containingmTOR-interacting protein), which
act as negative regulators of the complex by inhibiting the
binding of its substrates [14–16]. In addition, this complex
contains the mLST8 protein (mammalian lethal with Sec13
protein 8; also known as G훽L); however, the function of
this last component is still unclear [15–17]. On the other
hand, Complex 2 (mTORC2) encompasses six different com-
ponents including mTOR, mLST8, Deptor, Rictor, mSIN1,
and Protor 1/2 [16, 18–20]. In particular, the catalytic sub-
units mTOR and mLST8 and the negative regulator Deptor
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Figure 1: mTOR structure and components. In mammals, the mTOR kinase interacts with several proteins to form two functionally distinct
multiprotein complexes, namely, mTORComplex 1 (mTORC1) andmTORComplex 2 (mTORC2).The dashed line indicates the components
shared between mTORC1 and mTORC1.
represent a common feature of both mTOR Complexes 1
and 2. Moreover, mTORC2 is equipped with the scaffold
protein Rictor (rapamycin-insensitive companion of mTOR),
the protein mSIN1 (mammalian stress-activated map kinase-
interacting protein 1), which helps the complex assembly,
and Protor 1/2 (so called protein observed with Rictor-1 and
Rictor-2) [18–22]. In 2010 Kaizuka and colleagues [23] iden-
tified two other proteins (Tti1 and Tel2) which assemble with
both mTORC1 and mTORC2 complex. These two mTOR-
interacting proteins have been found to be essential for the
stability and the assembly of this multiprotein complex. In
fact, authors demonstrated that the knockdown of either
Tti1 or Tel2 causes the disruption of mTOR functional
activity [23].The differences betweenmTORC1 andmTORC2
are not merely based on their protein components since
these complexes are involved in the regulation of different
major cellular processes (Figure 1). In particular, mTORC1 is
mostly involved in cell growth and proliferation in response
to energetic and nutritional conditions [24] (Figure 2).
Nutrient availability (such as amino acids), cellular energy
status (oxygen and AMP/ATP ratio), growth factors, and
other extracellular and environmental stimuli may activate
mTORC1, which in turn acts on protein synthesis through
a wide number of downstream substrates and in particular
on the molecules of the translational machinery responsible
for the recruitment of mRNA (4E-BP1, p7026K, and S6
ribosomal protein) [13, 25, 26]. mTORC1 is also involved
in regulating lipid biogenesis which is necessary for cell
membrane generation and therefore cell growth and pro-
liferation. In fact, it has been demonstrated that mTORC1
positively regulates the activity of two transcriptional factor,
SREBP1 (sterol regulatory element binding protein 1), and
PPAR훾 (peroxisome proliferator-activated receptor 훾), which
are involved in controlling the expression of genes coding for
proteins linked to lipid and cholesterol homeostasis [27, 28].
Moreover,mTORC1 regulatesmetabolism andmitochondrial
biogenesis by modulating the transcriptional activity of the
nuclear cofactor PGC1-훼 (PPRA훾 coactivator 1) [29, 30].
Furthermore, mTORC1 is a negativemodulator of autophagy,
the main way of removing and recycling misfolded or long-
lived macromolecules, and even entire damaged organelles
(mitochondria, ribosomes, and endoplasmic reticulum) [31–
35].This latter processworks in baseline conditions but can be
either up- or downregulated depending upon specific needs.
When a defect in the autophagy pathway occurs, a variety
of cell mechanisms are altered and several consequences
may be produced. In the last decade, the impairment of
autophagy was related to a wide spectrum of human diseases
including type II diabetes, neurodegenerative conditions and
tumors as well [1, 36–38]. In contrast, mTORC2 is insensitive
to nutrients and it responds mostly to growth factors and
hormones to control actin cytoskeleton organization by phos-
phorylating several kinases such as Akt, SGK1, and PKC훼
[1, 10] (Figure 2). When compared to mTORC1, the function
of mTORC2 is less explored.The dearth of knowledge about
mTORC2 signaling pathways ismainly due to lethality caused
by the deletion of mTORC2 components during embryonic
development. We also lack specific mTORC2 inhibitors.
Only mTORC1 is sensitive to rapamycin [7].This natural
compound, produced by Streptomyces hygroscopicus bacteria,
and its analogs (rapalogs) represent allosteric inhibitors
which prevent mTORC1 recruitment of the mTOR catalytic
subunit, leaving intact the mTORC2 activity [2, 3, 39–
43]. Originally mTORC2 was thought to be a rapamycin-
insensitive companion of mTORC1 [18, 21]. However, further
studies demonstrated that, at least in some cell line, a
prolonged rapamycin administration may inhibit mTORC2
function as well [44].
2. mTOR Signaling Pathway in Neurons
In cells, mTOR activation requires the integration of a variety
of stimuli which in turn lead to several biochemical down-
stream reactions governing cell growth and metabolism.
In neurons, major mTOR upstream inputs include amino
acids (e.g., leucine and arginine) [45, 46], neurotrophic
growth factors, and neurotransmitters [47]. In fact, mTOR is
activated by a large number of growth factors encompassing
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Figure 2: mTOR signaling in neurons. The cartoon summarizes the main pathways placed both upstream and downstream to mTOR. The
activation of mTORC1 is elicited by a variety of upstream signaling molecules such as growth factors (e.g., BDNF, NGF, and IGF1), hormones
(e.g., insulin), and amino acids and neurotransmitters (e.g., glutamate) via the stimulation of various receptors.These include RTKs (Receptor
tyrosine kinases), GPCRs (G-protein coupled receptors), channel receptors, and cytokines receptors. Conversely, stimulation of NMDA
receptor decreases mTOR activity. Even hypoxia and energy defect enhance TSC complex activity, which in turn leads to mTOR inhibition.
The main downstream effects of mTORC1 are reported. Classically mTORC1 activates protein synthesis, translation, lipid biogenesis, and
mitochondrial biogenesis, while autophagy is under the negative control of mTORC1. In contrast, mTORC2 is not sensitive to nutrients and
it is mostly activated by growth factors and hormones to control cell survival and cytoskeletal organization.
BDNF (brain-derived neurotrophic factor), IGF1 (insulin-
like growth factor 1), VEGF (vascular endothelial growth
factor), CNTF (ciliary neurotrophic factor), and NRG-1
(neuregulin-1), all of them stimulating their specific tyro-
sine kinase (RTKs) receptor [47–50]. Most pathways which
activate mTORC1 converge in inhibiting the TSC1-TSC2
(hamartin-tuberin) complex, a heterodimer which, in turn,
is a strong endogenous mTOR inhibitor [51], while amino
acids activate mTORC1 independently from TSC complex
(Figure 2). In particular, mTORC1 activation is elicited by the
inactivation TSC complex via its phosphorylation on specific
sites through different kinases such as canonical Akt, RSK
(ribosomal S6 kinases), or even IKKB (I휅B kinase 훽) [51].
Moreover, several molecules other than neurotrophic
factors, such as guidance molecules, may either activate or
inhibit mTOR activity. For instance, previous studies demon-
strated that ephrin (Eph) is essential for axonal guidance by
its inhibitory role on neuronal mTORC1 [52]. On the other
hand, mTORC1 is activated by the reelin, an extracellular
matrix protein, in order to regulate dendritic growth and
branching [53, 54]. Again, many G-protein coupled receptors
(GPCPs) have been reported to activate mTOR signaling
in neuronal cells such as glutamate metabotropic mGlu1/5,
AMPA, dopamine D1 and D3, GABAB, and serotonin 5-
HT6 receptors [47, 55–59]. Conversely, the activation of the
glutamate NMDA receptor reduces intracellular arginine,
which decreases mTORC1 activity [60, 61]. Accordingly, the
NMDA receptor antagonist ketamine was found to quickly
activate the mTORC1 pathway [62, 63].This latter effect leads
to synaptogenesis in the prefrontal cortex of rat [62, 63].
In contrast only few data are available about upstream and
downstream mechanisms bound to mTORC2 in neurons.
For instance, mTORC2 activation may be induced by neu-
rotrophic growth factors rather than nutrients, while the
inhibition of its activity seems to be related to mTORC1
overactivation [64, 65] (Figure 2).
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Figure 3:The role of mTOR signaling in Glioma Stem/Progenitor Cells (GSPCs). mTOR is involved in neural stem cells (NSCs) proliferation,
migration, differentiation, axonal and dendritic development, synaptic plasticity, learning, and memory storage. Aberrant mTOR signaling
alters neural development and produces brain malformations in a wide spectrum of neurological disorders including neurodegeneration
and brain tumors. In fact, mTOR governs the proliferation and maintenance of NSCs within normal CNS.These stem cell niches are placed
within the subependymal ventricular zone of cornu temporalis nearby the cornu ammonis anddentatus gyrus of hippocampus. Several reports
demonstrate that a fine spatiotemporal tuning ofmTOR expression in the forebrain is essential for normal brain physiology and development.
Thus, enhanced activation of mTOR may lead to brain malformation and neurodevelopmental disorders. In GBM, Glioma Stem/Progenitor
Cells (GSPCs), which represent the amplification of normal stem cell niches, have been reported to support microvascular proliferation
and to promote infiltration into the surrounding tissues. Moreover, these cells are key for GBM progression, radio- and chemoresistance
and recurrence. Among several pathways which have been implicated in the maintenance and viability of GSPCs population, the marked
upregulation of mTOR is key in fostering cancer stem cells self-renewal and malignant phenotype.
3. mTOR-Dependent Brain Development and
Adult Neurogenesis
As occurring in all peripheral tissue, even in the central ner-
vous system (CNS), the mTOR pathway is involved in many
physiological functions such as cell growth, proliferation,
migration, protein synthesis, and transcription [1, 4, 6, 13, 25,
66, 67]. Among these pathways, transcriptional control and
protein synthesis are fundamental in the adult CNS due to
their key role in synaptic plasticity. In this way, modification
in those neuronal circuitries may alter learning and memory.
This calls for an in-depth experimental analysis of the effects
induced by long-term mTORC1 inhibition which may be
induced therapeutically by rapamycin or rapalogs. In fact,
apart from therapeutic effects, or systemic short-term side
effects, there is no study which specifically addresses how
the brain is modified by a long-term mTORC1 inhibition.
This calls for ad hoc experiments designed to evaluate poten-
tial behavioural or movement alterations and their poten-
tial neurochemical and neuroanatomical basis. Remarkably,
mTORC1-induced plastic events are dependent on novel
protein synthesis. In fact, mTORC1 participates in early CNS
development by regulating maintenance of neural stem cells,
neuronal differentiation,migration, and axonal and dendritic
development [68–84] (Figure 3). Even adult neurogenesis,
which persists in adult mammals, has been shown to be an
mTOR-dependent cellular process. This occurs in specific
adult brain regions known as neurogenic niches which are
the source of adult neuronal stem cells [77, 85–89]. Thus, it
is not surprising that disruption or dysregulation of mTOR
signaling pathway results in abnormalities of neuronal devel-
opment and brain malformations causing a wide spectrum
of brain disorders such as autism, seizures, and mental retar-
dation syndromes [59, 78, 90–93]. The effects of mTORC1
disruption in the adult brain need consistent experimental
efforts. Among all the components which constitute mTOR
complexes, those which have been examined more in depth
in the nervous system are themTORcatalytic subunit, Raptor,
Rictor, and mSIN1. Several reports have showed that mTOR
is essential for normal brain physiology and development
[17, 94–98]. In particular, the first evidence came from a
genetic screening which led to the isolation of selective
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mutations affecting the early telencephalon patterning [99].
One of the four isolated mutants, named flat-top, revealed a
specific lack of the telencephalon due to a disrupted signaling
pathway which regulates telencephalic primordia expansion
and regionalization. Noteworthy these flat-top mutant mice,
owning a single nucleotide intronic mutation which resulted
in aberrant splicing and decreased mTOR activity, showed a
failure of telencephalic vesicles progression [94]. Moreover,
it has been demonstrated that mTOR null mice die shortly
after implantation at early embryonic stages (E6.5–7.5), even
before the active proliferation of neural progenitors, which
start generating cortical neurons from embryonic day 10
to day 17 [17, 95, 96]. Whereas the complete deletion of
mTOR results in the lack of telencephalon and early death
of mice embryos, it has been recently demonstrated that
even overactivation ofmTOR leads to pathological alterations
in brain development. For instance, mutant mice carry-
ingmTORgain-of-functionmutations (CAG-mTORSL1+IT/+;
Emx1cre/+) at early embryonic stages showed an atrophic
cerebral cortex, while the mTOR overactivation in postmi-
totic neurons from late embryonic stages or postnatal period
leads to cortical hypertrophy and severe epileptic seizures [78,
100].Thus, a fine spatiotemporal tuning of mTOR expression
in the forebrain is likely to be key for preserving CNS
development.
Again, the complete ablation of mTOR components other
than the catalytic subunit results in embryonic lethality in
mice [17, 101]. For instance,mice embryos deficient for Raptor
or mLST8 die at early developmental stages, around E6.5
and E10.5, respectively, suggesting that these components are
essential for mTOR proper function [17]. Consistent with
previous reports [17, 94–96], it has been demonstrated that
the disruption of the mTORC2 specific component Rictor
is lethal at early embryonic stages in mice. When compared
with their wild-type littermates, Rictor null embryos showed
growth arrest between E9.5 and E10.5 and then die by E11.5
[101]. Remarkably, a very recent study showed that silencing
Rictor gene expression by RNAi (RNA interference) does not
enable mouse one-cell stage embryo to enter into the two-
cell stage normally [102]. In particular, the lack of Rictor
expression dramatically decreased the egg cleavage of mouse
one-cell stage embryo, which was blocked at G2 phase.
Therefore, these data suggest that Rictor-mTORC2/Akt1
pathway is essential for earlymitotic division in early embryos
[102].
Since knockout (KO) mice with a complete loss of mTOR
showed a severe phenotype with specific defect in telen-
cephalon formation and death during early/mid gestation
[17, 78, 95, 96, 99, 101, 102], conditional knockout (CKO)
mice were fundamental to elucidate the functional role of
mTOR in the brain [77, 78, 87, 88]. Recent CKO mouse
studies have demonstrated that the disruption of mTOR
signaling in the brain causes alteration in the homeostasis
of neural progenitors due to unbalanced self-renewal and
differentiation processes [76–78, 94, 96]. Remarkably, Ka et
al. [77] showed that in conditional mTOR knockout mice
(mTORloxP/loxP; Nestin-cre) the deletion of mTOR in neural
progenitors reduces neuronal layers within the developing
cerebral cortex. Thus the cerebral cortex appeared to be
markedly reduced in both weight and thickness at patho-
logical examination. Moreover, recent studies found that
mTOR activity was impaired in the NSCs of aged brain.
In particular, mTOR activity was decreased within NSC
niches in adult and aging forebrain [86, 103]. Accordingly,
ketamine-inducedmTOR signaling activation increases adult
NSCs proliferation in agedmice thus reducing age-associated
decline in neurogenesis [103].This evidence strongly suggests
that mTOR-mediated signaling is key in the maintenance of
NSCs and affects neuronal differentiation. Again, Zhang et
al. [81] showed that mTOR signaling amplifies adult NSCs
and progenitor cells which are crucial during hippocampal
neurogenesis, which is associated with spatial learning and
memory. In fact, within adult subgranular zone (SGZ) the
rate of neurogenesis is regulated by a gene silencer (enhancer
of zeste homolog 2, Ezh2), which promotes the amplification
of active NSCs and progenitor cells acting through the Pten-
Akt-mTOR pathway. In particular, Ezh2 suppresses Pten
expression and promotes the activation of Akt-mTOR [81].
In vivo Exh2 deletion decreases mTOR activity and reduces
proliferation of progenitors cells, which leads to impaired
learning and memory in Ezh2-null mice [81].
In keeping with the role of mTOR in proliferation
and migration of neural precursors, Lafourcade et al. [104]
showed that mTOR hyperactivation in neural progenitor
cells (NPCs) leads to migratory heterotopia, ectopic neuron
placement, and abnormal neuronalmorphogenesis. Increases
in mTOR activity in neonatal NPCs of the subventricular
zone (SVZ) of wild-type mice by electroporating a consti-
tutively active Rheb-encoding vector (RhebCA), an mTOR
positive upstream regulator, cause migratory heterotopia in
the rostral migratory stream (RMS) and olfactory bulb (OB).
Notably, these effects were prevented by rapamycin adminis-
tration, thus validatingmTOR involvement in these neuronal
morphogenesis defects [104]. Migratory heterotopia at cor-
tical level represents a major mechanism of epileptogenesis.
Remarkably, very recent manuscripts emphasized the role
of mTOR upregulation and reduced autophagy as causal
mechanisms in epileptogenesis and epilepsy-induce neuronal
damage [105].
Thus, mTOR plays a specific role within CNS for normal
development which encompasses neurite elongation and
branching, dendritic spine formation, synaptic consolidation
and plasticity, memory storage, and cognition.
Some findings regarding dendritic and axonal growth are
sometimes contradictory. This may be due to variability of
in vitro models with minor differences in culture conditions
[73, 74, 83, 106, 107]. Although further studies are needed in
vivo in order to confirm the role ofmTOR indevelopment and
neurogenesis the prevalent evidence indicates that mTOR
is crucial for synaptic plasticity [70–72, 75, 108–110]. For
instance, recent studies demonstrate than mTOR contributes
to hippocampal synaptic plasticity strengthening long-term
potentiation (L-LTP) [68, 70, 71, 75]. In Tsc2+/− mice the
overactivation of hippocampal mTOR leads to abnormal
hippocampal LTP in the CA1 region [72]. In particular, the
reduced threshold for hippocampal LTP produces abnormal
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learning. These effects were reversed by administering the
mTOR inhibitor rapamycin [72].
4. mTOR Related Neurological Disorders and
Brain Tumors
Over the past decades, Akt-mTOR signaling has increasingly
garnered a central role in regulating several molecular and
biochemical pathways which are known to be altered in
a variety of pathological conditions encompassing obesity,
cardiovascular diseases, hypertension, type II diabetes, neu-
rodegeneration, and brain tumors [37, 38, 66, 67, 111]. In
the CNS a wide spectrum of psychiatric, neurological, and
neurodegenerative disorders has been related to deregulated
mTOR signaling pathway. Several mutations in mTOR regu-
latory genes (e.g., TSC1, TSC2, LYK5/STRADA, AKT3, and
DEPDC5) enhance activation of mTOR and lead to brain
malformation and neurodevelopmental disorders. This is
the case of Tuberous Sclerosis Complex (TSC), hemimega-
lencephaly (HME), focal cortical dysplasia (FCD), Pretzel
syndrome (Ps), and familial focal epilepsy with variable foci
(FFEVF) [112–117]. Noteworthy, administration of mTOR
inhibitors is frequently beneficial for treating some neu-
rological alterations such as epilepsy, autism, and learning
disabilities [118–123].
Among primary brain tumors the most common are
gliomas which account for 80% of malignant CNS tumors.
The majority of gliomas (about 76%) are astrocytoma [124,
125]. Several human studies provided strong evidence on the
key role of an altered mTOR signaling pathway in low-grade
astrocytoma, such as subependymal giant cell astrocytoma
(SEGA), a rare, slow-growing benign tumor (WHO grade
I) which mainly occurs in young patients [126, 127]. Based
on this evidence, pharmacological inhibition of mTOR with
sirolimus and everolimuswas provided [128, 129] and, in 2010,
everolimus was approved by FDA as an alternative to surgical
resection for TSC-associated SEGApatients [130–133]. Again,
several reports have found that mTOR pathway is frequently
activated in other low-grade astrocytomas such as pediatric
low-grade glioma (PLGG) and pilocytic astrocytoma (PA)
[134, 135], while to date there are only few morphological
studies regarding the role of mTOR in anaplastic astrocytoma
(WHO grade III glioma) [136–138]. In contrast, there is
increasing evidence of mTOR upregulation in both exper-
imental and human Glioblastoma Multiforme (GBM). As
witnessed by multiple experimental and neuropathological
findings [139–141], mTOR upregulation is key in developing
GBM aggressive phenotype [142–145].
5. mTOR Upregulation as a Key to Understand
the Neurobiology of GBM
The biology of glioblastoma is characterized by prominent
proliferation, active invasiveness, and rich angiogenesis,
mainly due to highly mutated and/or deregulated signaling
pathways within the tumor [146, 147]. Growing knowledge of
these signaling pathways improved our understanding of the
biology and clinical behaviour of GBM. Remarkably, several
reports show that glioblastoma is more resistant to apoptosis-
inducing therapies, rather than autophagy-inducing thera-
pies [148, 149]. GBM resistance to conventional proapoptotic
chemotherapy and radiotherapy results from changes at the
genomic, transcriptional, and posttranscriptional level in key
molecules involved in mitogenic signaling, mostly in the
PI3K/PTEN/Akt axis, in tyrosine-kinases receptors (RTKs)
and their ligands, and in regulatory molecules and effectors
of the apoptotic cell death pathway [148, 150].
Several aberrant antiapoptotic signals conferring intrinsic
resistance to conventional and targeted anticancer therapies
have been described in GBM [149]. For instance, up to 70%of
GBMhave an alteration of tumor suppressor gene PTEN [124,
148, 151].This results in constitutive and increased activation
of several downstream effectors of the signaling pathways
controlled by PI3K, of which themost important identified to
date is PTEN/PI3K/Akt/mTOR, which plays a critical role in
the regulation of gene expression and prevention of apoptosis
[139, 150].
GBM consists of heterogeneous populations of poorly
differentiated tumor cells and it is characterized by a necrotic
area that can present foci of micronecrosis surrounded by
hypercellular zones, near to the normal tissue, of infiltrates
derived from parenchymal tissue. These cells surrounding
the necrotic foci are organized to form pseudopalisades with
a configuration that is typically exclusive of glial tumors
[152]. Intensemicrovascular proliferation and infiltration into
the surrounding tissues occur [153]. This is supported by
the presence of niches containing stem/progenitor cells of
GBM.
In the last decade, consistent evidence indicates that
within the tumors (mostly hematopoietic and solid tumors)
there is a fraction of cells, the cancer stem cells (CSCs),
which share characteristics with normal stem cells, such
as self-renewal potential and maintained proliferation, and
thus can initiate and sustain the tumor [154–156]. These
cells also have the ability to propagate the tumor in an
orthotopic xenograft transplantation model, when compared
with the nontumorigenic cells within the tumor bulk [157].
This theory, known as “The Cancer Stem Cell Hypothesis,”
has been proposed for the first time by Reya and colleagues in
2001. Nowadays, such fraction of cells has also been identified
in GBM, known as Glioma Stem/Progenitor Cells (GSPCs)
[158, 159]. In particular, these cells, which represent the
amplification of normal stem cell niches placed within the
subependymal ventricular zone of cornu temporalis nearby
the cornu ammonis and dentatus gyrus of hippocampus, have
been reported to support microvascular proliferation and to
promote infiltration into the surrounding tissues [160–162].
It is also very likely that GSPCs are responsible for GBM
progression, radio- and chemoresistance, and recurrence
[159, 163, 164]. Several pathways have been implicated in the
regulation and maintenance of GBM cancer stem cells pool.
Among them, the most important is the PI3K/Akt/mTOR
which, as aforementioned, needs to be properly and tightly
regulated in order to ensure a wide number of physiological
processes (i.e., proliferation, metabolism, survival, differen-
tiation, and autophagy) [38]. In GSPCs the marked upregu-
lation of mTOR has been related to increased proliferation,
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invasiveness, and resistance to standard treatments (Fig-
ure 3).Thus, aberrant Akt/mTOR signaling pathway strongly
correlates with GBM malignancy and poor prognosis [142–
145]. Growing evidence shed the light on the involvement of
PTEN/Akt/PI3K/mTOR signaling in maintenance and via-
bility of GSPCs population [141–145, 165, 166]. For instance,
Garros-Regulez et al. [145] have demonstrated that pharma-
cological inhibition of mTOR in glioma stem cells (GSCs)
causes a reduction in the expression of SOX2 and SOX9,
which are required for neural stem cell maintenance, thus
decreasing GSCs self-renewal potential and proliferation.
Moreover, it has been demonstrated that the lack of differ-
entiation of GSPCs is related to mTOR-dependent autophagy
inhibition [142, 158, 167–171]. Among several pathways which
are modulated through mTOR signaling, this molecular
complex plays a major role as an endogenous autophagy
inhibitor [172]. Notably, autophagy depression represents a
hallmark of GBM, as confirmed by several pathological stud-
ies carried out on human high-grade astrocytoma samples
[140, 168, 173, 174]. Several biochemical findings demonstrate
the remarkable effects of autophagy activators as powerful
inducers of cell differentiation, with a strong prevalence
towards neuronal phenotypes [142, 171, 175–180]. Remarkably,
autophagy activation has demonstrated a beneficial effect in
a variety of gliomas [172–182]. Again, GSPCs cell migration
and infiltration, which represent key mechanism for GBM
progression and infiltration within the surrounding normal
brain tissue, rely on mTOR upregulation and autophagy
suppression [165, 171]. Experimental evidence was recently
provided by our group showing that the mTOR inhibitor
rapamycin produces a remarkable suppression of GBM cell
proliferation both in vitro and in vivo in xenografts. In detail,
rapamycin produces a time- and dose-dependent suppression
of GBM cell proliferation when tested both in GBM cell
lines and primary cell cultures fromGBMpatients [168].This
effect is remarkably similar to U87MG cell lines and patient-
derived primary cell cultures and is not accompanied with
a cytotoxic effect. It is rather a suppression of cell growth,
as shown by cytofluorometry and Ki-67 immunostaining,
which is responsible for antiproliferative activity induced by
mTOR inhibition. The rapamycin-administered GBM cells
possess an increase in autophagy (ATG) vacuoles and develop
a progressive differentiation towards a neuron-like pheno-
type [168]. Remarkably, the mTOR suppression induced by
rapamycin is not accompanied by increased in pAkt/Akt ratio
ruling out the risk of a rebound Akt overactivation. It is
worth mentioning that the volume suppression induced by
rapamycin in vivo in xenografted GBM appears to surpass
the magnitude of antiproliferative activity. In fact, the tumor
volume which is measured following rapamycin administra-
tion is way reduced compared with tumor volume which
was already present before rapamycin was administered
[183]. Since such an effect occurs in the absence of any
apoptotic, necrotic, or gliotic area, what is the fate of the
previous volume filled with GBM since following rapamycin
this appears to be regularly shaped as specific CNS tissue
remains to be established [183]. Specific experiments aimed
at deciphering a potential phenotypic rescue of malignant
GBM cells back to differentiated neural tissue are currently
in progress in our lab. In fact, a few months ago we found
that rapamycin while inhibiting cell proliferation produced a
massive stemness regression in vitro as measured by classic
antigens. This occurs in association with the expression of
early and late neural differentiationmarkers, such asNeuroD,
beta-III tubulin, and NeuN, respectively. Remarkably, this
phenotypic shift is concomitant with suppression of GBM
cell migration [171]. All these events are backed up by
specific epigenetic effects of rapamycin on stemness and
differentiation genes.Despite the innumerous cascadeswhich
reside under the modulation of mTOR, the ATG machinery
appears to be the most likely to counteract GBM progres-
sion. In fact, the very same doses of rapamycin produce
a remarkable increase in ATG vacuoles and promote the
merging of the proteasome pathway within ATG vacuoles
to produce a fusion organelle named autophagoproteasome
[184].The shuttling of proteasome within ATG vacuoles was
recently demonstrated to depend on the recognition of the
ATG protein p62 which translocate proteasome components
within LC3-positive ATG vacuoles [185]. While low doses of
mTOR inhibition increase the ATG compared with protea-
some activity, high doses of rapamycin, way in excess to those
required to inhibit GBM proliferation, produce a prevalence
of proteasome over ATG activity.The ATG-inducing doses of
rapamycin range between 5 and 10 nM which correspond to
the amount of rapamycin considered to be in the therapeutic
range in humans as an immunosuppressant [3, 186]. The
very same range of doses fills the dose response curve
for the therapeutic effects of rapamycin we measured in
experimental GBM [168, 171]. It is noteworthy that, as it was
demonstrated in vivo [183], these doses of rapamycin are not
effective in producing apoptosis [168] and do not exert any
cytotoxic effects in GBM cells [171]. Altogether these data
pose the intriguing hypothesis that mTOR inhibition may
remodel the anaplastic GBM cell population stimulating “a
rebours,” a phenotypic differentiation shift. In other words,
inhibiting mTOR in glioblastomamay suppress an overactive
neural stem cell proliferation readdressing this exuberant
cell population towards the original phenotypes. Dedicated
experiments are needed to provide definite validation of these
early data and to establish the concomitant alterations which
may occur in the healthy areas of the CNS under the effects
of prolonged mTOR inhibition.
Nowadays a number of clinical trials are ongoing to
evaluate the effects of mTOR inhibition with rapamycin (or
rapalogs) based on the exciting results obtained both in
vitro in glioblastoma cell lines and in preclinical in vivo
models of GBM. Nonetheless, conflicting data still exist on
rapamycin and rapalogs treatments for high-grade astrocy-
tomas [187, 188]. For instance, it has been reported that
rapamycin inhibition of mTORC1-mediated S6K phosphory-
lation causes the block of a negative feedback loop which in
turn promotes the activation of mitogenic pathways such as
PI3K/Akt and Ras/MEK/ERK [189]. The activation of these
latter pathways causes an mTORC2 and Akt hyperactivation
through other feedback loops, which may contribute to
GBM metabolic reprogramming and drug resistance [190–
192]. Since mTOR inhibition promotes hyperactivation of
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the PI3K/Akt pathway, which could limit the drug treatment
efficacy, most of current trials take advantage of combined
therapies by administering dual PI3K-mTOR inhibitor or
new generation compounds such as ATP-competitive mTOR
inhibitors, which inhibit both mTORC1 and mTORC2 [166,
191–198]. However, the extent of the crosstalk between these
molecular complexes is not fully understood, since to date
only few upstream effectors and downstream substrates of
mTORC2 have been identified. A careful analysis of these
report demonstrate that such a feedback activation of Akt
under the effects of mTOR inhibition is indeed very rare
in human patients and it is more frequent to observe the
opposite effect [168].
6. Summary
The mammalian Target of Rapamycin (mTOR) is a mul-
tiprotein complex equipped with kinase activity which
belongs to the serine/threonine protein kinase (PI3K-related
kinase, PIKK) family. The mTOR catalytic subunit, which
nucleates two functionally distinct complexes (mTORC1
and mTORC2), is a key mediator of the PI3K/Akt/mTOR
signaling which controls cell growth, proliferation, and
metabolism. mTOR signaling is essential for normal devel-
opment and physiology of nervous system. In fact, several
physiological brain functions depend on mTOR activation.
Increasing evidence demonstrates that mTOR is critical for
maintaining the stemness of neural stem cells, neuronal
differentiation and migration, and axonal and dendritic
development. In addition, in adult brain synaptic plasticity,
learning and memory storage require a fine modulation
of mTOR activity. Therefore, dysregulation of this pathway
has been implicated in numerous pathological conditions
encompassing cancer, obesity, type II diabetes, neurologi-
cal and psychiatric disorders, neurodegeneration and brain
tumors, and mostly astrocytomas.
As witnessed by multiple experimental and neuropatho-
logical findings, mTOR upregulation plays a major role in
the development of the aggressive phenotype of glioblas-
toma (GBM, WHO grade IV astrocytoma), thus influencing
prognosis and determining response to therapies. Although
standard treatment options for GBM patients provide max-
imal surgical resection, in combination with chemotherapy
(with temozolomide, TMZ) and radiotherapy, it becomes
increasingly clear that modulation of mTOR activity repre-
sents an important molecular target. It should be mentioned
that mTOR inhibitors have not demonstrated therapeutic
potential in clinical trials against glioblastoma so far. An
intense clinical investigation is going on with approximately
twenty current clinical studies using mTOR inhibitors for
the treatment of gliomas. However, phase II studies reported
no efficacy of temsirolimus in combination with temo-
zolomide, sorafenib, bevacizumab, or erlotinib in recurrent
glioblastoma [199]. In any case, understanding the role of
mTOR in brain development and neurogenesis will con-
tribute to elucidate the pathological mechanisms of several
neurological, neurodevelopmental, and neurodegenerative
disorders.
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